T-SPORIN
Eye Drops
Cyclosporin Nanoemulsion 0.05%
Indications
Increased tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca.
T-SPORIN Eye Drops
(Single-dose)
Product Specifications
Cyclosporin Nanoemulsion 0.05%
Research &
Clinical Data
T-SPORIN's efficacy is supported by extensive clinical research demonstrating superior outcomes in dry eye treatment through advanced nano-emulsion technology.
Clinical Efficacy of Nano-emulsion Cyclosporine in Dry Eye Treatment
A comprehensive study demonstrating the superior efficacy of nano-emulsion cyclosporine formulation compared to traditional emulsions in treating keratoconjunctivitis sicca.
Read Full StudySafety and Tolerability Profile of T-SPORIN Eye Drops
Comprehensive safety analysis showing reduced side effects and improved patient comfort with nano-emulsion technology.
Read Full StudyLong-term Outcomes of Cyclosporine Nano-emulsion Therapy
Multi-center clinical trial results demonstrating sustained improvement in tear production and corneal health over extended treatment periods.
Read Full StudyKey Clinical Findings
Clinical studies demonstrate T-SPORIN's superior performance in multiple efficacy measures
Nano-emulsion
Technology Benefits
T-SPORIN's advanced nano-emulsion formulation provides significant clinical advantages over traditional cyclosporine preparations, delivering superior patient outcomes and enhanced therapeutic benefits.
Enhanced Efficacy
Nano-emulsion technology delivers superior therapeutic outcomes compared to traditional cyclosporine formulations, with improved bioavailability and faster onset of action.
Reduced Side Effects
Significantly decreased burning sensation and ocular irritation. The nano-emulsion formulation provides better tolerability and improved patient compliance.
Lower Infection Risk
Advanced nano-emulsion technology creates a more uniform, transparent liquid that reduces contamination risk and provides enhanced safety for long-term use.
Improved Anti-inflammatory Action
More effective suppression of ocular inflammation with uniform distribution across the eye surface, leading to better corneal and conjunctival health outcomes.
Superior Clinical
Outcomes
Based on recent clinical studies, T-SPORIN nano-emulsion cyclosporine demonstrates significant improvements in tear film breakup time (TBUT) and corneal damage scores compared to traditional emulsion formulations.
Exclusive Macau
Distribution Rights
WUZHOU DRUG INTERNATIONAL TRADING LIMITED
澳門五洲藥物國際貿易有限公司
澳門電廠巷22號亨達大廈地下AJ座
HANLIM PHARM.CO.LTD.
한림제약주식회사
- • Good Manufacturing Practice (GMP) Certified
- • ISO 13485 Quality Management System
- • Korean FDA Approved Facilities
- • International Quality Standards
Contact Us &
Message Board
Have questions about T-SPORIN or interested in distribution opportunities? Send us a message and our team will respond promptly.